BioCentury
ARTICLE | Company News

Agios sags after discontinuing PKD program

December 16, 2016 11:23 PM UTC

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) sank $10.87 (19%) to $45.07 on Friday after discontinuing development of AG-519 to treat pyruvate kinase deficiency. The company said Thursday after market hours that FDA placed a clinical hold on the candidate. Agios had been monitoring a drug-related case of cholestatic hepatitis in a healthy volunteer in a Phase I study (see BioCentury Extra, Dec. 15)...

BCIQ Company Profiles

Agios Pharmaceuticals Inc.

BCIQ Target Profiles

Pyruvate kinase R